Fusion Antibodies have been shortlisted for a category at the 2018 Northern Ireland Dealmakers Awards

Fusion Antibodies are absolutely delighted to be shortlisted in the Deal of the Year (£2.5m – £10m) award category in the Insider Northern Ireland Dealmakers Awards 2018! 
The Insider Northern Ireland Dealmakers Awards is an opportunity to celebrate the achievements of Northern Ireland’s corporate M&A professionals. 

The annual event – which recognises the sector’s best performances over the past year – is always eagerly awaited and hotly contested, with the winners set to be unveiled at the gala dinner taking place at the Belfast Waterfront on 15 March 2018.
It’s a night to show what this community can really do and to acknowledge excellence. 
Read more about these awards and see the shortlists here. 

We’re delighted to announce that we have some new services launching in 2018!

Developability and Manufacturability Services!

We have developed a range of software analytics delving into the properties of antibodies. These include in silico analytics such as;

  • Aggregation Potential
  • Hydrophobicity Potential
  • Deamidation Sites
  • N-Glycosylation Sites
  • Disulphide Bonds (Free Cysteines)
  • Oxidation sites
  • Proteolysis Sites
  • Potential expression improvement sites

Additionally, we are developing a range of wet lab techniques to complement our humanization services. These might include;

  • Analytical Size Exclusion Chromatography
  • Analytical Ion Exchange Chromatography
  • HIC (hydrophobic interaction chromatography)
  • Other HPLC analytics
  • DSC (differential scanning calorimetry)
  • Analytical/investigative SPR analysis

Antibody Affinity Maturation Services!

In 2018, Fusion Antibodies will be offering our affinity maturation services to the market. Affinity maturation is a platform we don’t currently offer but are excited about our solution in development.

We expect a late-R&D version of the platform to be available (at a reduced cost) within the next 3-6 months, followed by an official launch of the platform approximately 6-9 months from now. We can’t yet share much detail on the platform, but we can say that it will be proprietary, revolutionary & will take a modernised approach which will save costs and time to get to the clinic when compared to the other platforms on the market.  

Visit our website for a full list of services and future offerings or view our online brochure

Fusion Antibodies to seek AIM IPO

We are delighted to announce that we are seeking a listing on the AIM Market of the London Stock Exchange and has published its AIM Admission Document which will be available to view here.

We propose to raise approximately £5.5 million via a conditional placing through our NOMAD and broker, Allenby Capital Ltd. It is expected that admission to trading on AIM will become effective at 8am on Monday 18 December and shares will trade under the AIM symbol FAB. We expect to have a market capitalisation on admission of c. £18.1 million.

Use of funds

The net proceeds of the placing will be used to expand our existing laboratory space, increase our sales and marketing efforts, for the development of new service lines, as well as providing additional working capital. We intend to expand our current laboratory space and have secured additional space in the building on our existing site, which will enable us to more than double our facility. We intend to complete the fit out of the new laboratory by the end of 2018.

About Fusion Antibodies plc

Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using our proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, we have successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for our clients.

Fusion Antibodies was established in 2001 as a spin out from Queen’s University Belfast. We were initially a drug development business but revised our operations to focus on CRO work in 2011. We have recorded profits for the last two financial years, with annual sales of £1.9 million during the year ended 31 March 2017, and had an order book of £1.3 million as at 30 September 2017. In the six months to 30 September 2017, we recorded a turnover of £1.4 million. Our management team is highly experienced with a combined 47 years’ experience in the biopharma industry.

The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024.

Fusion Antibodies have an international, blue-chip client base, which includes eight of the top ten global pharmaceutical companies by revenue. A significant amount of our revenue is generated from follow on service requests from existing clients, providing good visibility of future earnings.

Our growth strategy is based on the expansion of our client base as well as the addition of new services including antibody affinity maturation and development of a mammalian antibody library. This strategy uses  our proven technology and expertise and targets expansion both in the UK market and internationally.


Existing shareholders of Fusion include venture capital firm Crescent Capital (also an investor in another Belfast firm, Andor Technology plc, which was bought by Oxford Instruments for c. £176m in December 2013), as well as Viridian Growth Fund (a NI focussed VC fund run by Belfast based Clarendon Fund Managers) QUBIS Ltd and Invest Northern Ireland. New investors include Hargreave Hale, Amati Global Investors, Unicorn AIM VCT and Octopus Investments.

Dr Paul Kerr, CEO of Fusion, commented: We are very pleased with the level of interest generated from new institutional investors in support of our AIM listing. When concluded we anticipate the placing to be oversubscribed and this demonstrates the strong support for our business strategy as we continue to invest in further growth across the business.

“We have established Fusion as a one-stop-shop for antibody engineering & humanisation, and cell line development for the world’s largest developers of antibody-based therapeutics drugs and diagnostics. We already have our first humanisation project in clinical trials and expect more to follow, and continue to grow the business having established a healthy forward order book. The move to AIM and the additional funding will allow us to continue this growth trajectory by expanding our capacity and developing our offering of new, high value, market differentiating products.”


Fusion Antibodies plcwww.fusionantibodies.com
Dr Paul Kerr, Chief Executive OfficerVia Walbrook PR
James Fair, Chief Financial Officer
Walbrook PRTel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManusMob: +44 (0)7980 541 893

Fusion Antibodies are pleased to be attending PEGS Europe being held on 13-17th November in Lisbon, Portugal.

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Last year, in 2016, a record number of delegates participated in PEGS Europe, as more than 800 attendees from 36 countries convened in beautiful Lisbon, Portugal to discuss the latest advances in protein and antibody engineering.

This year, PEGS Europe 2017 is expected to play host to over 900 delegates offering 200 technical presentations, 27 interactive breakout and panel discussionsas well as dedicated networking opportunities, making it an event to not be missed.  

Julie Gormley from the Fusion Team will be attending to share Fusion Antibodies unique offerings. Get in touch to organise a meeting.

To find out more information about PEGS Europe or to book your place, please visit their website.  

We look forward to seeing you!

Fusion Antibodies are delighted to be attending BioFIT being held on 28-29th November in Strasbourg, France.

BioFIT is the leading partnering event in Europe fortechnology transfer, academia-industry collaborations and early-stage innovations in the field of Life SciencesBioFIT is also the marketplace for pre-seed, seed and Series A investment in Life Sciences.

BioFIT attracts top international executives from established and emerging biotech companies, pharmaceutical/diagnostic companies, TTOs and academia, research institutions, institutional and private investors, services and consulting companies

This year, BioFIT is expected to play host to over 1,200 delegates and 60 speakers from over 800 organisations and 30 countries making it an event to not be missed. 

Paul Kerr and Julie Gormley from the Fusion Team will be attending to share Fusion Antibodies unique offerings. 

Get in touch to organise a meeting.

To find out more information about BioFIT 2017 or to book your place, please visit their website.  

We look forward to seeing you there!

Fusion Antibodies are attending BioJapan 2017 Pharma Event

Fusion Antibodies are pleased to be attending BioJapan 2017 being held on 11-13th October in Pacifico Yokohama, Japan.

Chris Moriarty from the Fusion Team will be showcasing his expertise at the UKti stand C- 48 in the UK Pavilion, so please drop by and meet him. 
BioJapan is Asia’s Leading Bio, Pharma R&D Event (Exhibition, Partnering, Conference) specialised in Biotechnology, Drug Discovery, Pharmaceutical Development, Regenerative Medicine and Personalised Medicine. The event has played an important role in facilitating interaction between Japanese and global organisations and stimulating new business opportunities for almost two decades. 
BioJapan 2017 is expected to feature 8000 partnering meetings, with delegates from over 30 countries attending as well as 900 participating companies.

To find out more information about BioJapan, please visit http://www.ics-expo.jp/biojapan/index.html

We look forward to seeing you!

Fusion Antibodies will be attending Bio-Europe 2017

Fusion Antibodies are pleased to announce that Chris Moriarty and Hayley Close from the Fusion Team will be attending Bio-Europe 2017, being held on 6-8th November in Berlin. 

Bio-Europe is Europe’s largest life science partnering conference. The conference brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled planning meetings and strategic panel discussions. 
This year’s conference is expected to see approximately 3,800+ executives and investors from the Biotechnology and Pharmaceutical industry gathering in Berlin, Germany to develop and grow new relationships.

To find out more information about Bio-Europe 2017 or to book your place, please click here
Get in touch with us today to arrange a meeting with Chris or Hayley. We look forward to meeting you there.

Fusion Antibodies North American Business Development Agent, Dr Jody Haddow pictured alongside Dr Alan Winter.

The recently retired CEO of Genome BC, Dr Alan Winter recently received a lifetime achievement award for his services at the British Columbia Life Sciences award Gala. A 1st Class Electrical and Electronics Engineering graduate from the Queen’s University of Belfast, Dr Winter was instrumental in helping design the ‘Canadarm’ on the space shuttle among many other achievements during his distinguished career.  Pictured is Dr Winter (right) alongside Fusion’s  North America Business executive, Dr Jody Haddow at the gala event.

The life science sector is a key sector and jewel in the crown for the UK economy. The sector contributes a massive annual turnover of £50 Billion, comprises of over 5,000 companies and employs an estimated 175,000 people.

The life science sector is a key sector and jewel in the crown for the UK economy. The sector contributes a massive annual turnover of £50 Billion, comprises of over 5,000 companies and employs an estimated 175,000 people.

Back in 2011, the ‘Strategy for UK Life Sciences’ was launched by then Prime Minister David Cameron in a long term aim of making the UK the global hub for life sciences in the future. The strategy set out a vision where academia, NHS, charities and industry would come together to create an unrivalled ecosystem. The strategy was designed around 3 main principles:

  1. Building a life science ecosystem
  2. Attracting, developing and rewarding best talent
  3. Overcoming barriers and creating incentives for the promotion of health care innovation

A report (From vision to action: delivery of the Strategy for the UK Life Sciences) released by LIfeScience UK in 2014 evaluated the ‘Strategy for UK Life Sciences’ was of mixed success so far. Projects as the ‘Biomedical Catalyst Fund’ which is £180 million fund jointly managed by the Medical Research Council and the Technology Strategy Board matched private funding to support medical research and innovation was successful as of 2014. Almost £125 million has been committed to accelerate numerous medical research projects, including over 100 business led projects.

However, some projects have been slow to come to action and deliver anything close to their objectives. For example, the ‘Innovation Scoreboard’ was designed to track the adoption of NICE Technology Appraisals (recommendations on the use of new and existing medicines and treatments within the NHS) at a local level. These are useful tools to enable NHS staff to understand their organisation’s performance in adopting innovation and for patients / public to exercise choice about their service provider. So far the Innovation Scorecard has become stagnant and is not yet detailed enough or aligned with the latest National Institute for Health and Care Excellence technology appraisals to inform patients and public about the availability of innovative treatments in the NHS. There is a long way to go before patients and NHS stakeholders will be able to understand the Innovation Scorecard.

The Clinical Practice Research Datalink (CPRD) is another success of the strategy, the CPRD is the observational data and interventional research service for NHS in England. The CPRD can link anonymised NHS clinical data to observation research beneficial to safeguarding and improving public health. The CPRD now holds a range of over-arching governance approvals that make under undertaking research on NHS databases far simpler. It connects patient information from GPs and hospitals to other records, such as registries and audit datasets, these combined datasets can be used to answer medical research questions.

Fusion Antibodies like other SME’s can also benefit from the Strategy. Life Science SME’s are increasingly taking a lead role in driving growth and innovation which the government recognises. SME’s can benefit from The Seed Enterprise Investment Scheme (SEIS) which offers tax relief at 50% of the cost of shares in qualifying companies, up to a maximum annual investment limit of £100,000. This allows smaller Life Science companies to gain investment more easily from private investors.

Fusion Antibodies applauds the positive developments undertaken since the start of the strategy such as the Biomedical Catalyst and the Clinical Practice Research Datalink, and also the increased collaboration between the NHS, academia, industry and the voluntary sector. Implementation of some government commitments has been inconsistent and yet to meet anything remotely near their goals so it is therefore essential that the government renew their efforts and get it right in order for the UK to remain at the pinnacle of scientific and medical advances.

To read more about the ‘Strategy for UK Life Sciences’ by the Department of Business Innovation & Skills, please visit here

To read more about the ‘From vision to action: delivery of the Strategy for the UK Life Science’  by the LifeSciences UK, please visit here

The Fusion Antibodies Team will be attending BioJapan 2016 held in Pacifico Yokohama, Japan this October.

BioJapan is Asia’s Leading Bio, Pharma R&D Event (Exhibition, Partnering, Conference) specialised in Biotechnology, Drug Discovery, Pharmaceutical Development, Regenerative Medicine and Personalised Medicine. Japan is the world’s 2nd largest pharmaceuticals and medical devices market. Japan is also recognised as leading the world in the regenerative medicine and cell therapy sector by easing regulations to allow early access to the market.

BioJapan has played a vital role in facilitating interaction between companies and organizations from Japan and abroad for almost 20 years. BioJapan 2016 is expected to feature 8000 partnering meetings, 15000 visitors and 800 participating companies.

 The Fusion Team (Dr Paul Kerr and Dr Richard Buick) will be attending from October 12th to 14th.

“I am looking forward to visiting Japan as it’s researchers are at the forefront of many new exciting immunotherapy treatments. Fusion has many collaborators in Japan and I am looking forward to meeting them in person and build on our relationship with Japanese researchers at BioJapan”

Paul Kerr. Managing Director at Fusion Antibodies

To find out more information about BioJapan, please visit http://www.ics-expo.jp/biojapan/index.html

To find out more information about Fusion Antibodies, please visit http://fusionantibodies.com/